In face of the dramatic evolution of the situation in Italy in the recent weeks, we have witnessed an increasing number of patients requiring ICU admission, during which extracorporeal circulation support therapies have often become necessary, including adjuvant therapies, such as sorbent therapy with CytoSorb.

Following the information previously provided and the experiences that have been taking place in the recent days, we consider important to share an update on the news related to the possible use of CytoSorb as an adjuvant therapy against some complications in patients with severe infection with COVID-19.

This document is for informative purposes only for clinicians who decide to undertake this type of therapy, emphasizing once again that sorbent therapy with CytoSorb is not a primary therapy for this type of pathology, but an adjuvant treatment to limit its and check for complications.

In this particularly critical moment, Aferetica wants to send its thoughts and wishes good work to the whole medical-scientific community, engaged in the front line in the fight against Coronavirus Covid-19.

DOWNLOAD THE UPDATE